Shopping Cart
- Remove All
- Your shopping cart is currently empty
Reltecimod TFA (AB-103 TFA) is a CD28 (T-lymphocyte receptor) mimetic that acts as a CD28 antagonist, inhibiting the stimulation of t-cells by a range of bacterial pathogens thereby attenuating acute inflammation for the treatment of necrotizing soft tissue infections (NSTI).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $32 | In Stock | |
10 mg | $52 | In Stock | |
25 mg | $106 | In Stock | |
50 mg | $172 | In Stock | |
100 mg | $255 | In Stock | |
200 mg | $378 | In Stock |
Description | Reltecimod TFA (AB-103 TFA) is a CD28 (T-lymphocyte receptor) mimetic that acts as a CD28 antagonist, inhibiting the stimulation of t-cells by a range of bacterial pathogens thereby attenuating acute inflammation for the treatment of necrotizing soft tissue infections (NSTI). |
In vivo | Reltecimod TFA, administered intravenously at dosages ranging from 1.25 to 5 mg/kg, has been shown to enhance survival rates in mice infected with various bacteria [1]. |
Alias | Reltecimod TFA, AB-103 TFA, AB103 TFA |
Molecular Weight | 1151.21 |
Formula | C48H73F3N10O17S |
Smiles | [H]N[C@@H](C)C(N[C@H](C(N1CCC[C@H]1C(N[C@@H](CCSC)C(N[C@H](C(N[C@H](C(N[C@@H](C)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)C(C)C)=O)CC(C)C)=O)=O)=O)CO)=O.OC(C(F)(F)F)=O |
Sequence | H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH |
Sequence Short | ASPMLVAYDA |
Storage | keep away from moisture,keep away from direct sunlight | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
Solubility Information | H2O: < 0.1 mg/mL (insoluble) DMSO: 80.00 mg/mL (69.49 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.